International Journal of Cancer Management

Published by: Kowsar

Primary Neuroendocrine Tumor of Liver (Rare Tumor of Liver)

Seyed Reza Mousavi 1 , * and Mahsa Ahadi 1
Authors Information
1 Cancer Research Center, Shohada Medical Hospital, Shahid Beheshti University Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: December 28, 2015, 8 (6); e3144
  • Published Online: December 23, 2015
  • Article Type: Case Report
  • Received: June 23, 2015
  • Revised: September 12, 2015
  • Accepted: November 7, 2015
  • DOI: 10.17795/ijcp-3144

To Cite: Mousavi S R, Ahadi M. Primary Neuroendocrine Tumor of Liver (Rare Tumor of Liver), Int J Cancer Manag. 2015 ;8(6):e3144. doi: 10.17795/ijcp-3144.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Footnotes
References
  • 1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998; 352(9130): 799-805[DOI][PubMed]
  • 2. Fenoglio LM, Severini S, Ferrigno D, Golle G, Serraino C, Bracco C, et al. Primary hepatic carcinoid: a case report and literature review. World J Gastroenterol. 2009; 15(19): 2418-22[PubMed]
  • 3. Knox CD, Anderson CD, Lamps LW, Adkins RB, Pinson CW. Long-term survival after resection for primary hepatic carcinoid tumor. Ann Surg Oncol. 2003; 10(10): 1171-5[PubMed]
  • 4. Zhang A, Xiang J, Zhang M, Zheng S. Primary hepatic carcinoid tumours: clinical features with an emphasis on carcinoid syndrome and recurrence. J Int Med Res. 2008; 36(4): 848-59[PubMed]
  • 5. Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery. 2015; 158(2): 339-48[DOI][PubMed]
  • 6. Valadares LJ, Costa Junior W, Ribeiro HS, Diniz AL, Coimbra FJ, Herman P. Resection of liver metastasis from neuroendocrine tumors: evaluation of results and prognostic factors. Rev Col Bras Cir. 2015; 42(1): 25-31[DOI][PubMed]
  • 7. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014; 15(1)-21[DOI][PubMed]
  • 8. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003; 133(4): 375-82[DOI][PubMed]
  • 9. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006; 13(4): 572-81[DOI][PubMed]
  • 10. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008; 144(4): 645-51[DOI][PubMed]
  • 11. Park CH, Chung JW, Jang SJ, Chung MJ, Bang S, Park SW, et al. Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. J Gastroenterol Hepatol. 2012; 27(8): 1306-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments